| Bioactivity | Pritumumab is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab recognizes vimentin expressing on the cell surface of the malignant tumor. Pritumumab can be used for glioblastoma research[1][2]. |
| In Vivo | Pritumumab 在裸鼠中有效阻止肿瘤生长，但在SCID小鼠中无效[1]。Pritumumab 只有在完整的细胞介导免疫存在的情况下，才能限制体内异种移植胶质瘤肿瘤的生长[1]。 |
| Name | Pritumumab |
| CAS | 499212-74-7 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Santosh Kesari, et al. Pritumumab binding to glioma cells induces ADCC and inhibits tumor growth. ASCO Annual Meeting I. 2017. [2]. Hugwil AV. The meaning of the anti-cancer antibody CLN-IgG (Pritumumab) generated by human × human hybridoma technology against the cyto-skeletal protein, vimentin, in the course of the treatment of malignancy. Med Hypotheses. 2013 Sep;81(3):489-95. |